| Literature DB >> 21438128 |
Giuseppina Basta1, Teresa Navarra, Paolo De Simone, Serena Del Turco, Amalia Gastaldelli, Franco Filipponi.
Abstract
Multiligand receptor for advanced glycation end products (RAGE) is expressed in a wide variety of tissues, including the liver. Interactions with its ligands lead to cellular activation and thus prolonged inflammation and apoptosis. RAGE also exists in a soluble, truncated isoform called soluble RAGE, which has the same ligand-binding specificity as membrane-RAGE; acting as decoy, it can contribute to the removal/neutralization of circulating ligands and the resultant reduction of signaling pathway activation. Experimental and clinical studies have highlighted the idea that the RAGE-ligand axis is involved in the development of liver fibrosis, inflammation, and regeneration after a massive injury and in the setting of liver transplantation. The involvement of the RAGE-ligand axis in vascular disease, diabetes, cancer, and neurodegeneration is well established, but it still needs to be clarified in the setting of liver diseases. We present a review of the recent literature on this receptor in surgical and clinical settings involving the liver, and we highlight the open issues and possible directions of future research.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21438128 DOI: 10.1002/lt.22306
Source DB: PubMed Journal: Liver Transpl ISSN: 1527-6465 Impact factor: 5.799